EK102HSS

Human IL-2 High Sensitivity Standard (人白介素2高敏 标准品)

X

¥280.00

因产品会迭代升级，具体实验步骤请按纸质版说明书操作

  • 分子靶点：IL2, IL-2
  • 种属：人 (Human)
  • 试剂盒：EK102HS
  • 保存：短期4℃保存，长期-20℃保存
  • 运输条件：4℃蓝冰运输

在售SKU:70-EK102HSS, 人白介素2, 白介素2, 人, 白介素, 2

描述

本产品只包含标准品试剂，如需购买试剂盒请点击下图

商品名

Human IL-2 High Sensitivity Standard (人白介素2高敏 标准品)
组分

人白介素2高敏标准品
检测方法

双抗夹心法
样本类型

血清，血浆，细胞培养上清及其他生物学样本
板式

管
保存

短期4℃，长期-20℃保存
运输条件

4℃蓝冰运输

检测原理：本试剂盒采用双抗体夹心酶联免疫吸附检测技术。特异性抗人IL-2抗体预包被在高亲和力的酶标板上。酶标板孔中加入标准品和待测样本，经过孵育，样本中存在的IL-2与固相抗体结合。洗涤去除未结合的物质后，加入生物素化的检测抗体孵育。洗涤去除未结合的生物素化的抗体，加入辣根过氧化物酶标记的链霉亲和素 (Streptavidin-HRP)。洗涤后，加入信号增强剂孵育，洗涤去除未结合的物质后，再次加入Streptavidin-HRP。洗涤后，加入显色底物TMB，避光显色。颜色反应的深浅与样本中IL-2的浓度成正比。加入终止液终止反应，在450 nm波长(参考波长570 - 630 nm)测定吸光度值。

Human IL-2 High Sensitivity ELISA Kit (人白介素2高敏 ELISA试剂盒) - 标准曲线
标准曲线

分子信息

概述人 IL2, IL-2 靶点信息

IL2 分子靶点信息概述

  • 分子名：IL2, interleukin 2
  • 基因家族：Interleukins
  • 别名：IL-2; TCGF
  • 全称：T cell growth factor

IL2 分子靶点综述

白细胞介素2(IL-2)是15kDa的糖蛋白，在人类中，由位于4号染色体q26–28区域的单基因编码。它是免疫系统中的一类信号分子，调控对具有免疫功能的白血球(白细胞，通常是淋巴细胞)的活性。IL-2是机体对微生物感染的天然应答，区别外来和自身抗原。IL-2通过与IL-2受体来发挥功能，其受体由3条链组成，分别为α链(CD25)、β链(CD122)和γ链(CD132)。监测血清中的IL-2含量为多种病理状态提供更详细的视角，包括癌症、传染病、移植排斥、多发性硬化症、类风湿性关节炎、系统性红斑狼疮和I型糖尿病等。

人 Human IL2 分子靶点信息

  • 分子名：IL2, interleukin 2
  • 别称：
    • aldesleukin
    • IL-2
    • interleukin-2
    • involved in regulation of T-cell clonal expansion
    • lymphokine
    • T cell growth factor
    • TCGF
  • 基因序列：NCBI_Gene: 3558
  • 蛋白序列：UniProtKB: P60568

人 Human IL2靶点分子功能（预测）

Enables cytokine activity and interleukin-2 receptor binding activity. Involved in leukocyte activation involved in immune response; positive regulation of interleukin-17 production; and positive regulation of tyrosine phosphorylation of STAT protein. Acts upstream of or within negative regulation of B cell apoptotic process; positive regulation of B cell proliferation; and positive regulation of activated T cell proliferation. Predicted to be located in extracellular space. Implicated in several diseases, including Takayasu's arteritis; auditory system disease (multiple); autoimmune disease (multiple); carcinoma (multiple); and neurodegenerative disease (multiple). Biomarker of several diseases, including Zellweger syndrome; aggressive periodontitis; anogenital venereal wart; autoimmune disease (multiple); and uveitis (multiple).

操作步骤

ELISA操作常见问题

血清OR血浆，哪个是ELISA的菜 

ELISA通关必备丨数据篇丨标准曲线不佳 

ELISA通关必备丨操作篇丨常见问题及解决方案 

ELISA通关必备丨操作篇丨溶解与稀释标准品 

ELISA通关必备丨样本篇丨不常见样本 

ELISA通关必备丨样本篇丨常见样本丨细胞 

ELISA通关必备丨如何选择试剂盒 

ELISA通关必备丨基础知识 

真？假？ELISA试剂盒选择要小心 

ELISA常见类型一 | 双抗夹心法，你要的都在这里！ 

ELISA常见类型二 | 竞争法，五分钟搞定！ 

叮！联科向您投递了个ELISA实验操作干货包，请查收~ 

【视频】ELISA实验操作步骤演示视频教程 

ELISA 组织样本的处理—大鼠组织 

【视频】ELISA实验原理与常见问题分析 

查看更多ELISA操作相关问题

引用文献

文章目录[隐藏]


  1. Inflammatory Cytokines Changed in Patients With Depression Before and After Repetitive Transcranial Magnetic Stimulation Treatment 

  2. Vitamin D deficiency is associated with thyroid autoimmunity: results from an epidemiological survey in Tianjin, China 

  3. Original research: Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma 

  4. Reducing Hinge Flexibility of CAR-T Cells Prolongs Survival In Vivo With Low Cytokines Release 

  5. Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma 

  6. Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy 

  7. Preclinical characterization of a Fab-like CD3/CLDN18.2 XFab® bispecific antibody against solid tumors 

  8. JAK-STAT Domain Enhanced MUC1-CAR-T Cells Induced Esophageal Cancer Elimination 

  9. Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression 

  10. Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager 

  11. Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy 

  12. Treatment Efficacy of Chuang Ling Ye, a Traditional Chinese Herbal Medicine Compound, on Idiopathic Granulomatous Mastitis: A Randomized Controlled Trial 

  13. Engineered IL-7 Receptor Enhances the Therapeutic Effect of AXL-CAR-T Cells on Triple-Negative Breast Cancer 

  14. Nanobody-based CAR T cells targeting intracellular tumor antigens 

  15. A PD-1 peptide antagonist exhibits potent anti-tumor and immune regulatory activity 

  16. Changes in peripheral blood cytokines in patients with severe fever with thrombocytopenia syndrome 

  17. Different effects of lipoteichoic acid from C. butyricum and S. aureus on inflammatory responses of HT-29 cells 

  18. The clinical study on treatment of CD19-directed chimeric antigen receptor-modified T cells in a case of refractory Richter syndrome 

  19. Protective Effect of Hedyotis diffusa Willd. Ethanol Extract on Isoniazid-Induced Liver Injury in the Zebrafish Model 

  20. Regulation of CBL and ESR1 expression by microRNA-22‑3p, 513a-5p and 625-5p may impact the pathogenesis of dust mite-induced pediatric asthma 

  21. Discovery of modulators for the PD-1/PD-L1 interaction by molecular simulation and bioassay 

  22. Hyperbaric Oxygen Alleviates the Inflammatory Response Induced by LPS Through Inhibition of NF-κB/MAPKs-CCL2/CXCL1 Signaling Pathway in Cultured Astrocytes 

  23. Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1–CH3 fusion protein 

  24. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12 

  25. Antigen presentation of the Oct4 and Sox2 peptides by CD154-activated B lymphocytes enhances the killing effect of cytotoxic T lymphocytes on tumor stem-like cells derived from cisplatin-resistant lung cancer cells 

  26. Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide 

  27. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3–Targeted Chimeric Antigen Receptor–Engineered T Cells in Hepatocellular Carcinoma 

  28. Effect of laser therapy on expression of angio- and fibrogenic factors, and cytokine concentrations during the healing process of human pressure ulcers 

  29. Expression of coinhibitory PD-L1 on CD4+CD25+FOXP3+ regulatory T cells is elevated in patients with acute coronary syndrome 

  30. Recognition and killing of cancer stem-like cell population in hepatocellular carcinoma cells by cytokine-induced killer cells via NKG2d-ligands recognition 

  31. Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial 

  32. Infant immune response to hepatitis B vaccine after fetal exposure to telbivudine 

  33. IFN-γ and TNF-α aggravate endothelial damage caused by CD123-targeted CAR T cell 

  34. Anemoside A3 activates TLR4-dependent M1-phenotype macrophage polarization to represses breast tumor growth and angiogenesis 

  35. Upregulation of MicroRNA 711 Mediates HIV-1 Vpr Promotion of Kaposi's Sarcoma-Associated Herpesvirus Latency and Induction of Pro-proliferation and Pro-survival Cytokines by Targeting the Notch/NF-κB-Signaling Axis 

  36. A novel membrane-bound interleukin-2 promotes NK-92 cell persistence and anti-tumor activity 

  37. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma 

  38. EGLIF-CAR-T Cells Secreting PD-1 Blocking Antibodies Significantly Mediate the Elimination of Gastric Cancer 

  39. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy 

  40. Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide 

  41. Ultrasound-Guided Percutaneous Transhepatic Gallbladder Drainage Improves the Prognosis of Patients with Severe Acute Cholecystitis 

  42. A metagenome-wide association study of the gut microbiota in recurrent aphthous ulcer and regulation by thalidomide. 

  43. Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56 

  44. Engineering of α-PD-1 antibody-expressing long-lived plasma cells by CRISPR/Cas9-mediated targeted gene integration 

  45. 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma 

  46. SHTXTHHly, an extracellular secretion platform for the preparation of bioactive peptides and proteins in Escherichia coli 

  47. Pyk2/MCU Pathway as a New Target for Reversing Atherosclerosis 

  48. Study on the Mechanism of Improving HIV/AIDS Immune Function with Jian Aikang Concentrated Pill Based on Network Pharmacology Combined with Experimental Validation 

  49. An intronic polymorphism of NFATC1 gene shows a risk association with biopsy-proven acute rejection in renal transplant recipients 

  50. Metabolic Reprogramming of CD4+ T Cells by Mesenchymal Stem Cell-Derived Extracellular Vesicles Attenuates Autoimmune Hepatitis Through Mitochondrial Protein Transfer 

  51. A nanobody-guided multifunctional T cell engager promotes strong anti-tumor responses via synergistic immuno-photothermal effects 

  52. Blocking the PD-1 signal transduction by occupying the phosphorylated ITSM recognition site of SHP-2 

  53. Self-reinforcing nano-spearhead drives the efficacy of CAR-T cells against progressive triple negative breast cancer 

  54. Targeting and cytotoxicity of chimeric antigen receptor T cells grafted with PD1 extramembrane domain 

  55. A dendritic/tumor fusion cell vaccine enhances efficacy of nanobody-based CAR-T cells against solid tumor 

  56. A role of NR4A2 in Graves’ disease: regulation of Th17/Treg 

  57. DCTPP1, a Reliable Q-Biomarker for Comprehensive Evaluation of the Quality of Tripterygium Glycoside Tablets Based on Chemical References 

  58. CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer 

  59. Universal chimeric Fcγ receptor T cells with appropriate affinity for IgG1 antibody exhibit optimal antitumor efficacy 

  60. Azithromycin attenuates wheezing after pulmonary inflammation through inhibiting histone H3K27me3 hypermethylation mediated by EZH2 

  61. A metagenome-wide association study of the gut microbiota in recurrent aphthous ulcer and regulation by thalidomide 

评价

目前还没有评价

成为第一个“Human IL-2 High Sensitivity Standard (人白介素2高敏 标准品)” 的评价者

您的电子邮箱地址不会被公开。 必填项已用*标注

相关产品